Highlights Ipsen

Equities

Market Closed - Euronext Paris Other stock markets 11:35:22 2024-05-31 am EDT			5-day change	1st Jan Change
120.6 ^EUR	+1.01%		-2.27%	+11.77%

May. 31	Ipsen: new employee shareholding operation	CF
May. 28	Ipsen S.A. Approves Dividend, Payable on 3 June 2024	CI

Ipsen: new employee shareholding operation	May. 31	CF
Ex-dividend day for final dividend	May. 29	FA
Ipsen S.A. Approves Dividend, Payable on 3 June 2024	May. 28	CI
IPSEN : Better-than-expected Q1; guidance unchanged	Apr. 24
Ipsen: sales up 11% in Q1	Apr. 24	CF
Ipsen Teams Up with Skyhawk Therapeutics on Study of RNA Modulator for Rare Neurological Diseases	Apr. 22	MT
Ipsen: collaboration agreement with Skyhawk	Apr. 22	CF
Ipsen and Skyhawk Therapeutics Announces RNA Targeting Research Collaboration in Rare Neurological Diseases	Apr. 22	CI
Ipsen: worldwide licensing agreement with Sutro Biopharma	Apr. 02	CF
Ipsen Signs Licensing Deal for Cancer-targeting Antibody Conjugate with Sutro Biopharma	Apr. 02	MT
IPSEN : Ipsen’s underlying fundamentals remain promising	Mar. 13
IPSEN : Deutsche Bank cuts its target	Feb. 16	CF
Ipsen: new indication approved in pancreatic cancer	Feb. 14	CF
Merrimack Pharmaceuticals to Get $225 Million Milestone Payment After FDA's Supplemental NDA Approval	Feb. 13	DJ
Ipsen?s Onivyde Regimen, Potential New Standard-Of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA	Feb. 13	CI
Ipsen S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 08	CI
IPSEN : In line Q4 sales; lower-than-expected 2024 guidance	Feb. 08
Ipsen: 13% drop in annual EPS	Feb. 08	CF
Ipsen presents positive data for Cabometyx	Jan. 23	CF
Ipsen Announces Latest Phase III Trial Data Investigating Cabometyx®? in Combination with Immunotherapy to Be Present at ASCO Gu 2024	Jan. 22	CI

No results for this search

IPSEN : Better-than-expected Q1; guidance unchanged

April 24, 2024 at 10:50 am EDT